Loading
Lifevantage Corp Stock: price and insider trades · United States
1 insider bought €5,260 of shares over the last 90 days, the latest by Lewis Darwin, filed 17 Sept 2026.
Lifevantage Corp: what insiders have been doing
This page follows insider dealings at Lifevantage Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Salt Lake City, United States. The group dates from 2003. The last twelve months, up to 22 October 2026, brought 42 filings signed by 13 insiders.
Both sides are active: 7 purchases worth €161k and 6 sales worth €408k, from 2 insiders and 2 insiders respectively. Sales outweigh purchases by €246k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €210k, the sale published on 10 November 2025 by Beindorff Michael A is the largest of the period. On the buying side, the filings list 2 senior executives among the declarants.
In the case of 4 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (17 September 2026) now reads 36 days. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 42 filings here. Our records for Lifevantage Corp go back to 2016, with 64 purchases and 32 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 30 June 2026 lists revenue at 182.6 m USD and net income at 5.1 m USD; the dividend was 0.18 USD per share.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
578
Thresholds
n/a
Buy Volume
€659,974
64 ops. · all time
Sell Volume
€2M
32 ops. · all time
Who traded when
BuySaleDarwin Lewis8 buys
Michael A. Beindorff7 sales
Judd Dayton3 buys
Mauro Garry Paul3 buys
Kristen Cunningham2 sales
Carl Aure1 sale
+2 other insiders
Since the insiders bought
- -6.0%Entry US$6.35 · Close 20 Oct 2026 US$5.97
- +96.5%Entry US$4.80 · Close at T+90 US$9.43
- -59.2%Entry US$12.56 · Close at T+365 US$5.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,259 of 26,246 companies
69.3
score / 100
Value70
Quality68
FCF yld8.9%
Earn yld6.7%
EV/EBITDA9.6x
ROE15%
Gross mgn78%
Net mgn2.8%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$5.97
Analyst consensus
2 analystsUS$6.00Target US$7.50(+26%)US$9.00
Income statement
RevenueUS$182.6M
Gross profitUS$141.6M78% margin
EBITDAUS$8.9M5% margin
Net incomeUS$5.1M2.8% margin
Valuation
PER (trailing)14.9x
PER (forward)15.4x
P/Book2.2x
Beta0.71
Balance sheet & cash
Market capUS$75.2M
Total debtUS$9.9M
Free Cash FlowUS$6.7M
Debt / Equity29%
Profitability & ownership
ROE14.9%
ROA6.2%
% insiders13.7%
% institutions53.2%
Last declaration on 9 October 2026
Declarations578 total
32,850 shares0Common StockSEC:0001193125-26-419109:0
35,749 shares0Common StockSEC:0001193125-26-419094:0
193,237 shares0Common StockSEC:0001193125-26-419076:0
460 shares@ US$6.240.0037% mcap1.8% of flowCommon StockSEC:0001193125-26-414130:0
637 shares@ US$6.240.0052% mcap1.9% of flowCommon StockSEC:0001193125-26-414128:0
976 shares@ US$6.220.0078% mcap1.0% of flowCommon StockSEC:0001193125-26-394331:0
Canonical exit: 14 Dec 2026 (T+90)
1,869 shares@ US$6.370.015% mcap7.3% of flowCommon StockSEC:0001193125-26-390924:0
2,254 shares@ US$6.370.018% mcap6.6% of flowCommon StockSEC:0001193125-26-390923:0
100 shares@ US$6.410.0008% mcap0.3% of flowCommon StockSEC:0001193125-26-390923:1
8,901 shares@ US$6.180.071% mcap25.4% of flowCommon StockSEC:0001193125-26-390923:2
308,642 shares0Common StockSEC:0001193125-26-342696:0
1,361 shares@ US$6.250.011% mcap5.4% of flowCommon StockSEC:0001193125-26-296262:0
1,717 shares@ US$6.250.014% mcap5.1% of flowCommon StockSEC:0001193125-26-296260:0
1,342 shares@ US$6.250.011% mcap6.6% of flowCommon StockSEC:0001193125-26-296258:0
10,000 shares@ US$8.54590.11% mcap6.7% of flowCommon StockSEC:0001193125-26-259533:0
10,000 shares@ US$8.730.11% mcap6.9% of flowCOMMON STOCKSEC144:0001949846-26-000342
1,527 shares@ US$4.204.0% of flowCommon StockSEC:0001193125-26-142102:0
8,180 shares@ US$4.201.8% of flowCommon StockSEC:0001193125-26-142098:0
1,928 shares@ US$4.203.8% of flowCommon StockSEC:0001193125-26-142097:0
1,446 shares@ US$4.204.7% of flowCommon StockSEC:0001193125-26-142103:0
1,055 shares@ US$5.230.9% of flowCommon StockSEC:0001193125-26-114085:0
Canonical exit: 14 Jun 2026 (T+90)
18,097 shares@ US$4.6315.4% of flowCommon StockSEC:0001628280-26-013462:1
Canonical exit: 28 May 2026 (T+90)
10,500 shares@ US$4.538.8% of flowCommon StockSEC:0001628280-26-013462:2
Canonical exit: 31 May 2026 (T+90)
4,600 shares@ US$4.586.1% of flowCommon StockSEC:0001628280-26-013462:0
Canonical exit: 27 May 2026 (T+90)
3,955 shares@ US$5.22163.4% of flowCommon StockSEC:0001628280-26-007303:0
Canonical exit: 10 May 2026 (T+90)
25 of 578 declarations
About Lifevantage Corp
LifeVantage Corp (NASDAQ: LFVN) is a U.S.-based health and wellness company headquartered in Lehi, Utah, United States. Founded in 2003, the company is best known for its focus on nutrigenomics, a field that examines how nutrition and naturally occurring compounds may influence gene expression and support wellness-related biological processes. For French-speaking investors, LifeVantage fits best as a niche player in preventive health and dietary supplements, with a direct-selling business model that relies heavily on an independent consultant network.
The company’s core business centers on health and nutrition products built around the idea of “activation” at the cellular level. Its portfolio includes Protandim-branded supplements, weight-management and metabolic wellness offerings, and broader health products. In 2025 and 2026, LifeVantage highlighted its MindBody GLP-1 System™, a product platform tied to current consumer interest in metabolism and weight management. The company also strengthened its portfolio through the integration of LoveBiome, which expanded LifeVantage into adjacent wellness categories and added another growth lever to the business.
Read moreShow less
From a competitive standpoint, LifeVantage operates in a highly fragmented market where success depends on brand differentiation, scientific credibility, distribution efficiency, and the ability to refresh the product lineup. The company emphasizes science-backed positioning and nutrigenomics-based messaging, but it faces intense competition from supplement companies, functional nutrition brands, and mass-market wellness players. Its international footprint is an important strategic advantage: beyond its U.S. base, LifeVantage has continued expanding the MB System internationally, including into Asia-Pacific, Europe, and other overseas markets.
Recent highlights include the international rollout of the MindBody GLP-1 System, the integration of LoveBiome, and continued product and commercial events designed to energize its consultant base. LifeVantage has also communicated fiscal 2026 financial guidance and continues to emphasize product innovation, global business events, and network activation as part of its growth strategy. For investors looking at a small-cap U.S.-listed wellness company on the NASDAQ, LifeVantage offers exposure to a science-oriented direct-selling model with growth potential that depends on product execution, international expansion, and the strength of its consultant-driven sales engine.
